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Abstract
Background: It has been shown in in-vitro experiments that “withdrawal” of tamoxifen inhibits growth of tumor
cells. However, evidence is scarce when this is extrapolated into clinical context. We report our experience to verify
the clinical relevance of “withdrawal therapy”.
Methods: Breast cancer patients since 1998 who fulfilled the following criteria were selected from the
departmental database and the case-notes were retrospectively reviewed: (1) estrogen receptor positive, operable
primary breast cancer in elderly (age > 70 years), locally advanced or metastatic breast cancer; (2) disease deemed
suitable for treatment by hormonal manipulation; (3) disease assessable by UICC criteria; (4) received “withdrawal”
from a prior endocrine agent as a form of therapy; (5) on “withdrawal therapy” for ≥ 6 months unless they
progressed prior.
Results: Seventeen patients with median age of 84.3 (53.7-92.5) had “withdrawal therapy” as second to tenth line
of treatment following prior endocrine therapy using tamoxifen (n = 10), an aromatase inhibitor (n = 5), megestrol
acetate (n = 1) or fulvestrant (n = 1). Ten patients (58.8%) had clinical benefit (CB) (complete response/partial
response/stable disease ≥ 6 months) with a median duration of Clinical Benefit (DoCB) of 10+ (7-27) months. Two
patients remain on “withdrawal therapy” at the time of analysis.
Conclusion: “Withdrawal therapy” appears to produce sustained CB in a significant proportion of patients. This
applies not only to “withdrawal” from tamoxifen, but also from other categories of endocrine agents. “Withdrawal”
from endocrine therapy is, therefore, a viable intercalating option between endocrine agents to minimise
resistance and provide additional line of therapy. It should be considered as part of the sequencing of endocrine
therapy.
Background
Estrogen receptor (ER) positive breast cancers after a
period of response to anti-estrogens develop resistance
and clinically the disease progresses. Besides the predo-
minant role of alternative signalling pathways, domina-
tion of partial agonistic activity of tamoxifen over its
antagonist activity has been implicated for acquired
resistance [1]. Regression of tumor on cessation of
tamoxifen therapy and the resultant clinical benefit (CB)
have been reported in several case-reports and series
[2-6]. In-vitro experiments have also shown that “with-
drawal” of tamoxifen inhibits growth of tumor cells [7].
We report clinical relevance of “withdrawal therapy”
from tamoxifen and other hormonal agents in patients
heavily pre-treated with endocrine therapy.
Methods
Case-notes of the breast cancer patients treated in the
Nottingham breast unit since 1998 fulfilling the follow-
ing criteria were studied retrospectively:
￿ ER positive invasive breast carcinoma proven by
histology (Standard Immuno-histochemically esti-
mated H score ≥ 50 accepted as ER +) [8]
￿ Primary operable cancer in elderly (age > 70 years)
(who were frail or refused to undergo surgery),
locally advanced or metastatic
￿ Disease deemed suitable for further hormonal
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suitable for “withdrawal” from an endocrine agent as
a therapeutic option (as opposed to a palliative
option)
￿ Assessable lesions were deemed to have shown CB
when they either had objective response in the form
of complete response (CR) or partial response (PR);
or had stable disease (SD) for ≥ 6 months in accor-
dance with UICC criteria [9,10]
￿ Metastatic lesions were assessed radiologically (CT
scan/X-rays/bone scan) every 3 months as routine
protocol in the unit
￿ On “withdrawal therapy” f o ra tl e a s t6m o n t h s
unless disease progressed prior
Duration of CB (DoCB) is the duration of therapy in
months only in patients who have derived CB and
including patient still on treatment. Duration of treat-
ment (DoT) is the duration of therapy in months of all
patients (regardless of the type of response) and includ-
ing patient still on treatment
Results
Seventeen patients with either locally advanced primary (n
= 3) or metastatic (n = 14) breast cancer had “withdrawal”
treatment as 2nd to 10th line of treatment. Patient and
tumor characteristics are shown in Table 1. Two patients
were still on follow-up at analysis. The results from “with-
drawal” from different agents are shown in the Table 2.
Drugs prior to withdrawal were mostly several lines of
endocrine agents (tamoxifen, aromatase inhibitors, AIs-
letrozole and exemestane, fulvestrant, megestrol acetate)
but some had radio and chemotherapy as necessary. How-
ever, in current study, only patients in whom the preced-
ing therapy was an endocrine agent were considered for
withdrawal (as mentioned in Table 2).
Discussion
Tamoxifen may continue to provide antagonistic activity
on ER nuclear signalling activity but may act as an
agonist on the ER membrane signalling activity which
could explain the loss of continuing CB to some patients
on long-term tamoxifen therapy [1]. There is significant
and sustained CB (60%) on “withdrawal” from tamoxifen
even in heavily pre-treated patients in our study. Pre-
vious studies have explained development of resistance
to tamoxifen itself due to clonal selection of breast can-
cer cells that grow in the presence of tamoxifen [4,6].
An in vitro study of cells derived from tumors of post-
menopausal patients which progressed on tamoxifen
showed growth enhanced by addition of tamoxifen [11]
suggesting domination of agonistic activity on long-term
tamoxifen therapy.
In an in-vivo study [12], athymic mice were trans-
planted with ER positive tumor cells and then exposed
to tamoxifen or placebo. The tumors regressed initially
over 4 months but started to grow towards the end of
the study (8 months) on long-term exposure to tamoxi-
fen and placebo. Tumors from both groups were re-
transplanted into athymic mice. Tumors which grew in
the presence of tamoxifen grew either on exposure to
estrogen or on exposure to further tamoxifen. In clinical
setting, therefore, cessation of further growth would be
expected on withdrawal of tamoxifen therapy at devel-
opment of resistance to tamoxifen. Our case-series and
previously reported case series confirm this finding in
clinical setting.
The lack of response in the remaining patients on
withdrawal of tamoxifen could partly be explained by
the growth promoting action of natural estrogen in the
body as seen in the above in-vivo study [12]. Therefore,
if “withdrawal therapy” from tamoxifen does not provide
any clinically beneficial response, an AI or fulvestrant
m a yb et h es u b s e q u e n te n d o c r i n ea g e n t so fc h o i c et o
negate the effects of persisting estrogen. This tactic of
manipulating hormonal environment of the tumor pro-
vides a viable intercalating option between endocrine
agents without possible side-effects.
In our study, as seen in table 2, there were a group of
patients who were on endocrine agents other than
Table 1 Patient and Tumour characteristics
Median age = 84.3 (53.7-92.5) years
Histopathology Invasive adenocarcinoma = 12 Mixed Tubular + Cribriform = 1 Not
available = 4
Median ER (estrogen receptor) H score 185 (IQR, 97.5-222)
Median Disease Free Interval (DFI) 84 (IQR, 19-180) months
Metastatic Sites Bone = 6
Pleura/Effusion = 4
Lung = 2
Liver = 5 Supraclavicular/mediastinal Lymph node = 2
Median lines of therapy prior to withdrawal 5 (range 1-9)
Median TTP (time to progression) on endocrine agent prior to
withdrawal
6 (IQR, 3-17) months
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fulvestrant). Therapy in these patients was withdrawn
either due to side-effects or patient unfitness/refusal. No
further endocrine therapy was instituted as they already
had multiple lines of other therapies. On routine clinical
follow-up, incidental responses were seen in these
patients. It is difficult to explain incidental responses to
withdrawal from categories of endocrine agents other
than tamoxifen or an AI. It could be due to paradoxical
action of natural estrogens rebounding after “withdra-
wal” of anti-estrogens without agonist activity [1,13]. In
an in-vitro study in MCF-7 cells by Masamura et al [14]
long-term estrogen deprivation (akin to usage of anti-
estrogens in the form of AIs clinically) led these cells to
develop estrogen hypersensitivity. In a long-term estro-
gen deprived aromatase resistant breast cancer cell
model (MCF-7:5C), Osipo et al [7] demonstrated apop-
tosis at a concentration of 10
-11 M/L or more of estra-
diol. This is again possible due to activation of cross-
talk mechanisms and domination of mitogen-activated
protein kinase or growth factors [1].
The above in-vitro concept is being explored further
in clinical settings. There is ongoing recruitment to a
phase III trial (SOLE trial, Study Of Letrozole Extension
trial) wherein node positive early stage patients who
have completed 4-6 years of prior adjuvant endocrine
therapy (a SERM/AI/both) are randomised to receive
either 5 years of daily letrozole or receive intermittent
letrozole regime (daily for first 9 months of 1
st 4 years
followed by 12 months in year 5)[15]. The rationale for
this study is that long-term estrogen deprivation by an
AI reduces the sensitivity of the tumour cells to therapy
and interruptions to therapy allows resurgence of estro-
genic stimulation leading to restoration of sensitivity to
letrozole on its reintroduction.
In locally advanced and advanced breast cancer, ide-
ally, inhibitors of the alternative pathways would be the
subsequent logical therapy following resistance to other
endocrine agents. However, if the patient is unfit to
receive any further anti-estrogen therapy then it is very
likely that they would not be suitable for further growth
factor inhibitors or indeed chemotherapeutic agents. In
this circumstance, withdrawal of therapy may be the
only feasible option or alternating regime of endocrine
therapy and withdrawal therapy as is being tested in the
adjuvant setting in the SOLE trial.
Conclusions
Our data therefore provides some clinical evidence and
emphasises the relevance of withdrawal therapy. The
concept is being tested in large randomised trials in
adjuvant settings. However, larger datasets and results of
ongoing adjuvant trials are needed to provide confirma-
tory evidence for or against the concept and feasibility
of withdrawal therapy in locally advanced and metastatic
breast cancer.
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